$CORT·8-K

CORCEPT THERAPEUTICS INC · Mar 25, 1:31 PM ET

Compare

CORCEPT THERAPEUTICS INC 8-K

Research Summary

AI-generated summary

Updated

Corcept Therapeutics Announces FDA Approval of Lifyorli for Ovarian Cancer

What Happened
On March 25, 2026, Corcept Therapeutics, Inc. announced that the U.S. Food and Drug Administration approved Lifyorli™ (relacorilant) in combination with nab‑paclitaxel for the treatment of adults with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The approval covers patients who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. Corcept filed an 8‑K (Item 8.01) and attached the company press release as Exhibit 99.1.

Key Details

  • Approval announced: March 25, 2026 (press release attached to the 8‑K).
  • Product: Lifyorli™ (relacorilant) used in combination with nab‑paclitaxel.
  • Indication: Adults with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Patient history requirement: 1–3 prior systemic regimens, with at least one including bevacizumab.

Why It Matters
This FDA approval is a regulatory milestone that allows Corcept to market Lifyorli for a defined ovarian cancer population and is material to the company’s oncology commercial strategy. For investors, the approval may affect Corcept’s near‑ and mid‑term commercial opportunity, future revenue potential, and the value of its oncology pipeline as the company moves to commercialize the new indication.

Loading document...